Landscape Capital Management L.L.C. Invests $329,000 in Biogen Inc. $BIIB

Key Points

• Landscape Capital Management L.L.C. acquired a new stake in Biogen Inc., purchasing 2,403 shares valued at approximately $329,000 in the first quarter.
• Institutional investors collectively own 87.93% of Biogen's stock, with significant increases in holdings from firms like Causeway Capital Management LLC, which grew its stake by 53.9%.
• Biogen reported $5.47 EPS for the last quarter, exceeding analyst estimates of $3.93, and anticipates posting 15.83 EPS for the current fiscal year.

Landscape Capital Management L.L.C. bought a new position in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 2,403 shares of the biotechnology company's stock, valued at approximately $329,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. B. Riley Wealth Advisors Inc. lifted its position in Biogen by 4.1% during the 4th quarter. B. Riley Wealth Advisors Inc. now owns 2,343 shares of the biotechnology company's stock worth $358,000 after acquiring an additional 92 shares during the last quarter. Quent Capital LLC lifted its position in Biogen by 31.2% during the 1st quarter. Quent Capital LLC now owns 391 shares of the biotechnology company's stock worth $54,000 after acquiring an additional 93 shares during the last quarter. CVA Family Office LLC lifted its position in Biogen by 71.1% during the 1st quarter. CVA Family Office LLC now owns 231 shares of the biotechnology company's stock worth $32,000 after acquiring an additional 96 shares during the last quarter. Private Trust Co. NA lifted its position in Biogen by 74.8% during the 1st quarter. Private Trust Co. NA now owns 229 shares of the biotechnology company's stock worth $31,000 after acquiring an additional 98 shares during the last quarter. Finally, BNP Paribas lifted its position in Biogen by 14.9% during the 4th quarter. BNP Paribas now owns 804 shares of the biotechnology company's stock worth $123,000 after acquiring an additional 104 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company's stock.

Insider Transactions at Biogen

In other Biogen news, insider Rachid Izzar sold 2,223 shares of the business's stock in a transaction dated Tuesday, July 8th. The shares were sold at an average price of $135.00, for a total value of $300,105.00. Following the transaction, the insider directly owned 6,330 shares in the company, valued at $854,550. The trade was a 25.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Priya Singhal sold 517 shares of the business's stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $133.55, for a total transaction of $69,045.35. Following the completion of the transaction, the insider owned 5,772 shares in the company, valued at approximately $770,850.60. This trade represents a 8.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.18% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on BIIB shares. Morgan Stanley dropped their price objective on shares of Biogen from $146.00 to $144.00 and set an "equal weight" rating on the stock in a report on Friday, August 1st. Truist Financial started coverage on shares of Biogen in a report on Monday, July 21st. They set a "hold" rating and a $142.00 price objective on the stock. Wedbush restated a "neutral" rating and set a $121.00 price objective on shares of Biogen in a report on Thursday, June 12th. Needham & Company LLC restated a "hold" rating on shares of Biogen in a report on Thursday, June 12th. Finally, Citigroup boosted their price objective on shares of Biogen from $125.00 to $135.00 and gave the stock a "neutral" rating in a report on Friday, August 1st. Eleven research analysts have rated the stock with a Buy rating and twenty-one have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $185.74.

Biogen Price Performance

NASDAQ:BIIB traded up $1.99 on Wednesday, reaching $141.62. The stock had a trading volume of 2,279,248 shares, compared to its average volume of 1,292,470. The company has a market capitalization of $20.76 billion, a P/E ratio of 13.54, a price-to-earnings-growth ratio of 1.04 and a beta of 0.11. Biogen Inc. has a 1-year low of $110.04 and a 1-year high of $206.50. The company has a quick ratio of 1.79, a current ratio of 2.50 and a debt-to-equity ratio of 0.36. The stock has a fifty day moving average price of $132.10 and a 200-day moving average price of $130.63.

Biogen (NASDAQ:BIIB - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The biotechnology company reported $5.47 EPS for the quarter, beating analysts' consensus estimates of $3.93 by $1.54. The firm had revenue of $2.65 billion for the quarter, compared to analyst estimates of $2.32 billion. Biogen had a net margin of 15.31% and a return on equity of 13.85%. The company's revenue for the quarter was up 7.3% compared to the same quarter last year. During the same period in the previous year, the business earned $5.28 earnings per share. Biogen has set its FY 2025 guidance at 15.500-16.000 EPS. Research analysts forecast that Biogen Inc. will post 15.83 EPS for the current year.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.